From SpringerLink ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1656 of 1668  at  9/25/2020 8:01:56 PM  by

vorlon1966

The following message was updated on 9/25/2020 8:08:32 PM.

 In response to msg 1654 by  auh2oman
view thread

Re: From SpringerLink ...

Just going to point this out. In a P1 stage IV combo study subset of patients of PV-10/Keytruda where all lesions were injected. 75% complete response and 81% ORR. Now a 24 patient cohort is undergoing recruitment of stage III in-transit mets where all lesions will be injected with PV-10 prior to addition of systemic Keytruda.

Preclinical trials underway of oral systemic PV-10 in addition to injected PV-10 because Poetic out of Calgary is showing preclinical efficacy of oral PV-10 in child leukemia. PV-10 going into systemic application research in addition to intralesional injections.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 128
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1657 Re: From SpringerLink ... vorlon1966 0 9/25/2020 8:20:06 PM
1658 Re: From SpringerLink ... vorlon1966 0 9/25/2020 8:20:07 PM






Financial Market Data provided by
.
Loading...